Search results
Results from the Health.Zone Content Network
DSM Headquarters in Heerlen, the Netherlands, pictured in 2011. Koninklijke DSM N.V. ( Royal DSM, commonly known as DSM, which is the acronym for Dutch State Mines ), [2] was a Dutch multinational corporation active in the fields of health, nutrition and materials. Headquartered in Heerlen, at the end of 2017 DSM employed 21,054 people in ...
List of largest biomedical companies by revenue. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) that have generated a revenue of at least US$ 10 billion, ranked by their revenue in the respective financial year. It does not include biotechnology companies that ...
Website. www .rossmann .de. Dirk Rossmann GmbH, commonly referred to as Rossmann, is one of the largest drug store chains in Europe with around 56,200 employees and more than 4000 stores. [2] [3] [4] In 2019 Rossmann had more than €10 billion turnover in Germany, Poland, Hungary, the Czech Republic, Turkey, Albania, Kosovo, Spain and Azerbaijan.
Skin irritation. Strong odor of garlic. More serious side effects include: Severe allergic reactions. Headaches. Itching and burning when applied to the skin. DMSO can also cause a deadly reaction ...
Uses. This combination medication is used to relieve coughs caused by the common cold, bronchitis, and other breathing illnesses. Guaifenesin belongs to a class of drugs known as expectorants. It ...
Aster DM Healthcare Limited is a multinational for-profit private hospital network founded by Azad Moopen in 1987. The company has its corporate headquarters in Dubai, UAE, and is registered in Bangalore, India. Aster DM Healthcare currently operates hospitals, medical centres, diagnostic centres, laboratories and pharmacies in six GCC ...
Find patient medical information for DM Cough oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.
The company's stock is trading 13.9 times its forward 12-month earnings estimates, compared with a forward price-to-earnings ratio of 34.2 for Novo Nordisk and 48.49 for Eli Lilly.